Unknown

Dataset Information

0

Modes and timing of death in 66?252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials.


ABSTRACT: Aims:Although presenting features and early sequelae of non-ST-segment elevation acute coronary syndromes (NSTE-ACS) are well described, less is known about longer-term risks and modes of death. The purpose of this study was to characterize modes of death following NSTE-ACS in clinical trial populations. Methods and results:We evaluated 66 252 patients with NSTE-ACS enrolled in 14 Thrombolysis in Myocardial Infarction (TIMI) trials, examining baseline characteristics and modes and timing of death. Of the 66 252 patients followed for a median of 372 (interquartile range 218-521) days, 3147 (4.8%) died by the time of last follow-up. Of the 2606 patients (82.8%) with known modes of death, 75.1% were related to a cardiovascular (CV) event, 3.0% were related to a bleeding event (including intracranial haemorrhage), and 21.8% were related to a non-CV/non-bleeding event. The most common modes of CV death were sudden death (SD) and recurrent myocardial infarction (MI) (36.4% and 23.4%, respectively, of CV deaths). The proportion of CV deaths related to recurrent MI was higher in the first 30?days than it was after 30?days following NSTE-ACS (30.6% vs. 18.7%), whereas the proportion of SD was lower in the first 30?days than after 30?days (21.6% vs. 46.2%). Conclusion:Sudden death represents the largest proportion of CV deaths after 30?days among patients enrolled in CV clinical trials with NSTE-ACS. Further investigations aimed at defining the epidemiology of SD and developing specific therapies and management approaches to reduce SD following NSTE-ACS may be critical to reducing late mortality.

SUBMITTER: Berg DD 

PROVIDER: S-EPMC6220126 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Aims</h4>Although presenting features and early sequelae of non-ST-segment elevation acute coronary syndromes (NSTE-ACS) are well described, less is known about longer-term risks and modes of death. The purpose of this study was to characterize modes of death following NSTE-ACS in clinical trial populations.<h4>Methods and results</h4>We evaluated 66 252 patients with NSTE-ACS enrolled in 14 Thrombolysis in Myocardial Infarction (TIMI) trials, examining baseline characteristics and modes and  ...[more]

Similar Datasets

| S-EPMC6279197 | biostudies-literature
| S-EPMC10382099 | biostudies-literature
| S-EPMC3426608 | biostudies-literature
| S-EPMC8616749 | biostudies-literature
| S-EPMC8413889 | biostudies-literature
| S-EPMC8414421 | biostudies-literature
| S-EPMC9159742 | biostudies-literature
| S-EPMC5898983 | biostudies-literature
| S-EPMC7891521 | biostudies-literature
| S-EPMC8310962 | biostudies-literature